Celcuity (CELC) Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying Opportunity
Celcuity (CELC) is in focus after receiving FDA approval for REVTORPYK for certain HR+/HER2- metastatic breast cancer patients, along with its inclusion as a preferred option in updated National Comprehensive Cancer Network treatment guidelines.
See our latest analysis for Celcuity.
Despite the REVTORPYK approval and guideline inclusion, Celcuity’s recent momentum has cooled, with the share price falling 22% over 30 days and 37.1% over 90 days, even as the 1 year total shareholder return sits at 66.9% and the 3 year total shareholder return is above 8x.
If you are looking beyond Celcuity for other potential healthcare opportunities, it could be a good time to scan 44 healthcare AI stocks.
Celcuity is now trading at a sizeable discount to both analyst targets and internal fair value estimates after a sharp pullback. Does that gap signal limited conviction, or a valuation reset that has gone too far?
Most Popular Narrative: 46.2% Undervalued
Celcuity’s most followed narrative pegs fair value at $161.09, which sits well above the last close at $86.60 and frames the recent sell off in a very different light.
Celcuity currently has no revenue. Analysts are forecasting revenue to reach $817.9 million by June 2029.
As a pre-revenue company, Analysts expect Celcuity to achieve a profit margin of 32.7% in 3 years time.
Curious how a pre revenue Celcuity narrative gets to this kind of valuation gap? The story hinges on sharp revenue scaling and a rich future profit multiple.
Result: Fair Value of $161.09 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Celcuity’s story could change quickly if future VIKTORIA data disappoints or if regulators require more evidence that slows or complicates approval timelines.
Find out about the key risks to this Celcuity narrative.
Next Steps
With Celcuity sitting between clear risks and potential rewards, it may be useful to move quickly and test the story against your own judgement. To see both sides set out in one place, review the 3 key rewards and 3 important warning signs
Looking for more investment ideas beyond Celcuity?
If Celcuity has sharpened your focus on stock selection, do not stop here. Broader research across quality watchlists can help you spot opportunities others might overlook.
- Target potential value opportunities by scanning companies highlighted in the 51 high quality undervalued stocks that may trade below their assessed worth and could warrant a closer look.
- Strengthen your focus on financial resilience by filtering for companies in the solid balance sheet and fundamentals stocks screener (49 results) that pair cleaner balance sheets with fundamental support.
- Hunt for underfollowed opportunities by checking the screener containing 18 high quality undiscovered gems where quieter stocks with solid metrics might be waiting before broader attention arrives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com